In addition, it has been hypothesized that the possible role of glucagon-like receptor agonists (GLP1-Ras) in the modulation and interaction of these two hepatokines could provide an explanation of the therapeutic potential for the treatment of MASLD with these drugs. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.